Please login first
Epaminondas Sidiropoulos   Dr.  University Educator/Researcher 
Timeline See timeline
Epaminondas Sidiropoulos published an article in August 2011.
Top co-authors
Zoe Dorothea Pana

14 shared publications

Aristotle University

Athanasios Tragiannidis

1 shared publications

Second Pediatric Department, Aristotle University of Thessaloniki, Ahepa General Hospital, Thessaloniki, Greece

Emmanuel Hatzipantelis

1 shared publications

Second Pediatric Department, Aristotle University of Thessaloniki, Ahepa General Hospital, Thessaloniki, Greece

Fani Athanassiadou

1 shared publications

Second Pediatric Department, Aristotle University of Thessaloniki, Ahepa General Hospital, Thessaloniki, Greece

Theodotis Papageorgiou

1 shared publications

Second Pediatric Department, Aristotle University of Thessaloniki, Ahepa General Hospital, Thessaloniki, Greece

1
Publication
0
Reads
0
Downloads
1
Citation
Publication Record
Distribution of Articles published per year 
(2011)
Total number of journals
published in
 
1
 
Publications
Article 0 Reads 1 Citation Transient myeloproliferative disorder in a newborn with down syndrome treated with rasburicase for the risk of developme... Athanasios Tragiannidis, Zoe Dorothea Pana, Theodotis Papage... Published: 24 August 2011
Journal of Medical Case Reports, doi: 10.1186/1752-1947-5-407
DOI See at publisher website PubMed View at PubMed ABS Show/hide abstract
Transient myeloproliferative disorder is a hematologic abnormality characterized by an uncontrolled proliferation of myeloblasts in peripheral blood and bone marrow that primarily affects newborns and babies with Down syndrome. Tumor lysis syndrome is rarely associated with transient myeloproliferative disorder. Transient myeloproliferative disorder was diagnosed in a seven-day-old baby girl with Down syndrome, who was referred to our department due to hyperleukocytosis. Our patient developed tumor lysis syndrome, successfully treated with rasburicase, as a complication of transient myeloproliferative disorder resulting from rapid degradation of myeloid blasts after initiation of effective chemotherapy. Tumor lysis syndrome is rarely reported as a complication of transient myeloproliferative disorder. To the best of our knowledge, this is the first case of a newborn with Down syndrome and transient myeloproliferative disorder treated with rasburicase for developing tumor lysis syndrome.
Top